ACRINAmerican College of Radiology Imaging Network
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Combined Screening with Ultrasound and mammography compared to mammography alone in women at elevated risk of breast cancer: results of the first-year screen in ACRIN 6666.
(12.) Lehman CD, Gatsonis C, Kuhl CK, Hendrick RE, Pisano ED, Hanna L, Peacock S, Smazal SF, Maki DD, Julian TB, DePeri ER, Bluemke DA, Schnall MD; ACRIN trial 6667 Investigators Group.
Berg WA, Blume JD, Cormack JB, et al, for the ACRIN 6666 Investigators.
Results from recent trials including the National CTC Trial conducted by the ACR Imaging Network (ACRIN) that demonstrated the effectiveness of virtual colonoscopy as a screening procedure, coupled with recent initiatives to establish Medicare reimbursement for the procedure, may increase the viability of virtual colonoscopy for colorectal cancer screening and are likely to drive increased utilization of the procedure.
Supplementing mammography with ultrasound raised the rate of diagnosis by 55% in the American College of Radiology Imaging Network (ACRIN) 6666 study, the largest randomized clinical trial to compare the performance of mammography plus ultrasound with that of mammography alone in high-risk women, according to the researchers.
Wendie Berg reported on behalf of the American College of Radiology Imaging Network (ACRIN) 6666 trial group at the annual meeting of the Radiological Society of North America.
Additional regulatory elements included the first intron of the rice acrin 1 promoter (McElroy et al., 1990), the 3' non-translated region of the nopoline synthase gene from Agrobacterium tumefaciens (Fraley et al., 1983), and an intron from the maize hsp70 gene (Brown and Santino, 1994).
The Digital Mammographic Imaging Screening Trial (DMIST) is funded by the National Cancer Institute and conducted by the American College of Radiology Imaging Network (ACRIN).
Women who refused breast MRI screening as part of the American College of Radiology Imaging Network (ACRIN) 6666 trial reported that the long scan times required and the claustrophobia of the magnet bore itself were reasons for their refusal to undergo a breast MRI as a supplemental breast cancer screening tool (15, 28).
DeMichele et al., "Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL-CALGB 150007/150012, ACRIN 6657," Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.
(3.) Berg WA, Blume JD, Cormack JB, et al; ACRIN 6666 Investigators.